TNFRSF10A and rheumatoid arthritis: It was shown that the modification did not alter COL2-specific immunity in a DR4+ RA patient, but was sufficient to induce T-cell activation and production of proinflammatory cytokines in a non-DR4+ patient with active disease [114].